🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

#Rstats users. How can I plot two non-competing Cumulative incidence variables? I could group those who have both as a certain status, but then it’s only reflective of the 1st event? Using ggsurvplot.

Adaptimmune Receives U.S. FDA Approval of TECELRA® (afamitresgene autoleucel), the First Approved Engineered Cell Therapy for a Solid Tumor #oncopharm adaptimmune.com/investors-and-…

Hot off the press, great team effort for #ID guidance in #CART: Best Practice Considerations by The American Society of Transplant and... sciencedirect.com/science/articl… Zainab Shahid MD, FACP, FIDSA 🇺🇸🇵🇰 Tania Jain M. Veronica Dioverti Nirali Shah genovefa papanicolaou Mehdi Hamadani, MD ASTCT

Just published in British Journal of Haematology - an updated BSH - Haematology good practice paper on the ever-controversial topic of CNS prophylaxis in LBCL! Pleasure to work with Kate Cwynarski Toby Eyre Jeff Smith Sridhar Chaganti @DrChrisPFox and Pam McKay on this... 1/2 onlinelibrary.wiley.com/doi/10.1111/bj…

Sustained remission following finite duration bispecific antibody therapy in patients with relapsed/refractory myeloma. ⁦Raj Chakraborty⁩ ⁦Meera Mohan⁩ #OpenAccess nature.com/articles/s4140…

You've heard of the nine circles of Hell? A patient with cancer documented the TWENTY-SIX steps necessary to get their medication (as an oncologist I know a vicious cycle when I see one)

Allogeneic Hematopoietic Cell Transplantation for the Treatment of Severe Aplastic Anemia: Evidence-Based Guidelines from the American Society for Transplantation and Cellular Therapy Transplantation and Cellular Therapy Journal astctjournal.org/article/S2666-…

【Aspergillus galactomannan false positive】 It's important to understand that there are various potential causes of false positives for Aspergillus galactomannan! Level: Intermediate to advanced #IDMedEd #IDFellow #IMResident #Aspergillus #TxID #HemOnc

Evaluation of primary oral vancomycin prophylaxis against C. difficile infection during autologous stem cell transplantation ✅ Just Accepted ✍️ Michael Williams 🔗 bit.ly/3YrpLO2

If you are in the area, come say hi!

Great, comprehensive option for science graphics, all free! I’ll definitely be using this starting with my current manuscript.

These new clinical practice guidelines provide a framework for decision-making regarding #alloHCT for Mycosis fungoides (MF) and Sézary syndrome (SS) and highlight areas for future prospective investigation. See the full guideline: astctjournal.org/article/S2666-…

FDA approves revumenib for relapsed or refractory acute leukemia with a KMT2A translocation. fda.gov/drugs/resource… #OCENewsBurst

With the use of PTCy, have there been any observations (anecdotal or published) of an uptick in liver GVHD? Bmt ctn 1703 doesn’t support this theory.

2024 approvals: Summary of 12 new 💊indications in heme malignancies U.S. FDA 1. #Zanubrutinib 2. #Ponatinib 3. #LisoCel x2 4. #Imetelstat 5. #Epcortimab 6. #Daratumuab 7. #Axatilimab 8. #Isatuximab 9. #Asciminib 10. #ObiCel 11. #Revumenib #HemeTwitter #OncTwitter #mmsm

Transplanting Hope: Managing Relapsed/refractory AML clinical-lymphoma-myeloma-leukemia.com/article/S2152-…

Reduced venetoclax exposure to 7 days vs standard exposure with hypomethylating agents in newly diagnosed AML patients Blood Cancer Journal nature.com/articles/s4140…

BREAKING: The FDA's ODAC has voted 8 to 1 against the applicability of the STARGLO trial findings for US patients with relapsed/refractory #DLBCL. This decision impacts the use of glofitamab (Columvi) with GemOx. #lymsm hubs.li/Q03nmsc90

Carl June is one name that reshaped medicine. This tribute article charts his journey from Navy doctor to #CART pioneer, highlighting how his vision and compassion launched a new era of cellular therapy and saved thousands of lives. Read the article: ow.ly/W1B050W2Amc